Institut Bergonié — Clinical Trial Site

11 Registered trials

2 Currently recruiting

Organisation

Institut Bergonié

Location

Bordeaux, France

Identifier

ORL-000005496

Address

229 cours de l'Argonne, 33076, France

Departments

Gastroenterology
Hématologie
Medical Oncology
Oncologie
Oncologie Médicale
Service Oncologie Urologie

Clinical trials at this site (11)

Search interface

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-02… Pending

2024-517339-30-00 Advanced Solid Tumors 7
A Study to Learn about the Study Medicine called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Pending

2025-523526-40-00 Advanced Solid Tumors 9
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer Recruiting

2023-510536-37-00 Prostate Cancer 4 2024-07-05
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult P… Ended

2024-510995-18-00 Advanced Solid Tumors 1 2023-03-01
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi… Ended

2023-509089-39-00 Non-Muscle Invasive Bladder Cancer 5 2020-07-01
First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended

2024-515560-30-00 Advanced-stage, relapsed/refractory cancer 7 2020-03-05
A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors Ended

2024-515175-35-00 Locally Advanced or Metastatic Solid Tumors 1 2021-02-10
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 stomach cancer 4